Product Overview
1-(2-Bromo-4-chlorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole is a halogenated heterocyclic compound used in the documented synthesis of asundexian.
Its molecular structure combines a 1,2,3-triazole ring, a trifluoromethyl substituent, and a phenyl ring bearing both bromine and chlorine atoms.
This combination is particularly useful in pharmaceutical synthesis because the two halogen substituents provide different opportunities for downstream chemical modification.
Product Information
- · Product Name: 1-(2-Bromo-4-chlorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole
- · CAS Number: 1445866-55-6
- · Molecular Formula: C₉H₄BrClF₃N₃
- · Molecular Weight: 326.50 g/mol
- · Chemical Class: Halogenated 1,2,3-triazole
- · Application: Asundexian intermediate
The molecular formula, molecular weight, and chemical identity are supported by PubChem and commercial chemical reference data.
Connection to Asundexian Synthesis
Asundexian, also known as BAY 2433334, is an oral Factor XIa inhibitor developed for the prevention and treatment of thromboembolic disorders.
Its molecular structure contains a chlorinated phenyl group connected to a trifluoromethyl-substituted 1,2,3-triazole ring. This structural unit is directly contributed by CAS 1445866-55-6.
A research paper published in the Journal of Medicinal Chemistry describes the synthesis of asundexian and identifies this compound as a key coupling partner in the route.
The reported sequence involves:
1. Preparation of a pyridone-containing boronic acid ester.
2. Suzuki coupling with 1-(2-bromo-4-chlorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole.
3. Subsequent ester deprotection and amide formation.
4. Final separation of the desired enantiomer in the research-stage route.
The coupling step is reported as part of a two-step sequence with a combined yield of 59%.
This published evidence establishes the compound’s direct role in asundexian synthesis.
Why the Bromine and Chlorine Substituents Are Important
One of the most important structural characteristics of CAS 1445866-55-6 is that it contains two different halogen substituents on the same aromatic ring.
1. Bromine as a Cross-Coupling Handle
The bromine atom is positioned at the 2-position of the phenyl ring.
In the published asundexian route, this position participates in palladium-catalyzed Suzuki coupling with a boronic ester.
This reaction connects the triazole-containing aromatic fragment to the pyridone-containing portion of the target molecular framework.
2. Chlorine Retention in the Final Structure
The chlorine atom is located at the 4-position of the phenyl ring.
Unlike bromine, this chlorine substituent is retained in the corresponding asundexian structure.
The distinction between these two halogen positions is important for understanding the compound’s synthetic value. The bromine provides a selective coupling site, while the chlorine remains part of the final molecular architecture.
3. Trifluoromethyl-Substituted Triazole Ring
The 4-(trifluoromethyl)-1,2,3-triazole group is another defining structural feature.
It forms part of the heterocyclic aromatic fragment incorporated into asundexian through the coupling sequence.
The trifluoromethyl substituent also makes control of the compound’s chemical identity and related impurities important during synthesis and quality evaluation.
Synthetic Route and Process Development Considerations
The synthesis of asundexian has been described in both research publications and patent literature.
The original research-stage route demonstrates the use of CAS 1445866-55-6 in a palladium-catalyzed Suzuki coupling.
More recent patent literature also discusses the preparation of asundexian and the limitations of earlier routes for larger-scale manufacturing, including lengthy sequences, purification requirements, and the need for chiral separation in certain approaches.
For intermediate suppliers, this creates several relevant quality-control considerations:
- · Control of the bromine-containing starting material’s identity and purity
- · Monitoring of possible positional isomers
- · Control of residual starting materials and related triazole impurities
- · Consistency of the halogenated aromatic structure
- · Evaluation of residual solvents and moisture
- · Reproducibility between production batches
The exact requirements should be agreed with the customer according to the intended downstream process.
Quality Requirements for B2B Buyers
When evaluating CAS 1445866-55-6, pharmaceutical manufacturers should consider the following quality attributes:
|
Evaluation Item |
Why It Matters |
| Chemical identity | Confirms the correct triazole and aromatic substitution pattern |
| HPLC assay | Measures the main-component content |
| Related substances | Helps identify structurally similar impurities |
| Positional isomers | Important because the bromine and chlorine positions determine downstream reactivity |
| Residual solvents | Supports process and product quality requirements |
| Water content | Helps assess material consistency and storage suitability |
| Batch reproducibility | Reduces variation in subsequent coupling reactions |
For Suzuki coupling applications, the impurity profile deserves particular attention. Unwanted isomers or related aromatic impurities may complicate downstream purification and affect the quality of the coupled product.
Buyers should therefore request a representative COA and, where appropriate, analytical information supporting the identity and impurity profile of the material.
Choosing a Pharmaceutical Intermediate Supplier
A reliable supplier should provide more than a product quotation. Buyers should evaluate the supplier’s ability to support consistent quality, technical communication, and supply continuity.
For CAS 1445866-55-6, relevant supplier capabilities include:
- · Consistent product specifications
- · Batch-specific analytical documentation
- · HPLC and structural identification support
- · Sample availability for process evaluation
- · Customized impurity specifications
- · Flexible supply arrangements
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. focuses on pharmaceutical intermediate R&D, custom synthesis, and manufacturing support.
Its company profile describes an R&D laboratory, pilot production workshops, and production equipment designed to support different reaction conditions and manufacturing scales.
For customers evaluating this Asundexian intermediate, technical discussions can cover product specifications, sample evaluation, impurity control, and customized supply requirements.
Further information is available through the official company profile.
Conclusion
1-(2-Bromo-4-chlorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole is a documented key intermediate in asundexian synthesis.
Its importance comes from the combination of a bromine-based cross-coupling handle, a chlorine substituent retained in the target structure, and a trifluoromethyl-substituted triazole ring.
For pharmaceutical buyers, reliable chemical identity, positional-isomer control, consistent assay results, and a reproducible impurity profile are essential considerations when sourcing this material.
A supplier with appropriate analytical and process-development support can help customers improve procurement confidence and downstream synthesis consistency.
Post time: Nov-13-2026
